INTRODUCTION
Use of all medical services, including prescription drugs, increases with age. The Medicare program, which provides government-sponsored health insurance benefits to elderly and disabled persons, does not pay for most prescription drugs for persons living in the community. By contrast, about 80 percent of persons employed in medium and large firms have health insurance benefits that include some form of outpatient prescription drug coverage (U.S. Department of Labor, 1994) .
There have been a variety of legislative proposals over time to add a drug benefit to Medicare. The Medicare Catastrophic Coverage Act, which would have added a limited drug benefit to Medicare, was passed in 1988 but repealed in 1989 before the drug benefit took effect. There are currently several proposals for Medicare drug coverage in Congress, including one that would raise cigarette taxes to pay for adding a drug benefit to Medicare (Convey, 1998) . Another proposal would legislate steep discounts for prescription drug purchases by Medicare beneficiaries (Lagnado, 1998) . The National Bipartisan Commission on the Future of Medicare, created by Congress in 1997 to examine possible options for restructuring Medicare benefits, recommended adding an outpatient prescription drug benefit to Medicare for persons with incomes at or below 135 percent of the Federal poverty level (National Bipartisan Commission on the Future of Medicare, 1999 ).
An earlier article (Davis et al., 1999) showed national data on drug insurance coverage, use, and spending for Medicare beneficiaries. In this article we provide more detail on the demographic characteristics and extent of coverage for Medicare beneficiaries with some form of prescription drug coverage. In future articles we will focus on characteristics of persons without such coverage and compare the two groups.
The data in this article were compiled from the MCBS 1995 Cost and Use File. The MCBS is a continuing panel survey of about 12,000 aged and disabled beneficiaries. The survey collects a wide variety of personal and health care-related information for persons living in the community and those living in long-term care facilities. In this article, however, we exclude persons who lived in a facility for all of their Medicare-eligible months and focus only on drug insurance coverage and spending for Medicare persons who lived in the community for all or part of the year. The "Data Sources and Methods" section provides more detail about the procedures used to assign persons to insurance categories and the methods used to collect drug coverage, use, and spending data. For a more complete description of the MCBS, refer to Adler (1994) .
FINDINGS
Approximately 65 percent of Medicare beneficiaries have some insurance coverage for prescription drugs (Table 1) . This percentage is higher than that reported in earlier studies, in part because of an improvement in methodology. For example, the count of covered persons now includes those who have more than one insurance source and receive drug coverage from a second or third source, not their primary. This change added about 1.2 million persons, or 3.4 percentage points, to the count. To simplify presentation and avoid very small numbers, however, persons with multiple sources of coverage were assigned to whichever insurance category was considered to be their primary Medicare supplement (a fuller discussion of the methodological changes is contained in the "Data Sources and Methods" section).
The largest source of drug coverage, by far, is employer-sponsored insurance. People in this category represent about 44 percent of all covered persons. Eighty-six percent of beneficiaries with employersponsored supplemental insurance have some form of drug coverage. Although recent data have suggested that the number of employers providing supplemental retiree coverage has been declining, MCBS data show an increasing percentage of beneficiaries with employer-sponsored coverage have a drug benefit.
About 17 percent of covered persons have Medicaid, the second-largest source of coverage. Not all persons classified with Medicaid have drug coverage, because this category includes Qualified Medicare Beneficiaries (QMBs) and Special LowIncome Beneficiaries (SLMBs), for whom the State pays the Medicare Part B premiums (buy-ins). This results in 90 percent of Medicaid-eligible beneficiaries receiving prescription drug coverage. The next largest source-individually purchased plans that are the primary source of health coverage-represents 16 percent of covered persons. Three of the 10 standardized medigap plans currently offered (which are included in the individually purchased category) contain a prescription drug benefit. Perhaps because of its expense, only 29 percent of persons with individually purchased plans have prescription drug coverage through that plan. Another 7 percent of beneficiaries with individually purchased supplemental plans obtain drug coverage from another source, leaving about twothirds of beneficiaries with individually purchased plans without drug coverage.
Nearly all beneficiaries enrolled in Medicare risk health maintenance organizations (HMOs) receive prescription drug coverage. These beneficiaries accounted for about 10 percent of persons with drug coverage in 1995. The number of Medicare beneficiaries joining risk HMOs appears to have risen in the past several years perhaps in part because of people wishing to obtain prescription drug coverage.
The extent of coverage varies somewhat by demographic characteristic, although, in many cases, this variation is directly attributable to the type of supplemental coverage, if any, the beneficiar y has. • Single, never-married beneficiaries had higher rates of coverage because of higher rates of Medicaid eligibility.
• Beneficiaries living in non-metropolitan areas were much less likely to have drug coverage than beneficiaries living in metropolitan areas.
• Roughly 70 percent of persons with incomes greater than $20,000 had coverage. Coverage was lowest-60 percentfor persons with incomes in the $10,000-$19,999 range-the category likely to be just above Medicaid levels.
PRESCRIPTION DRUG SPENDING
In general, household sur veys have been found to contain underreporting of costs and use of services because of lack of recall on the part of those being interviewed. Although several steps were taken to mitigate under-reporting (see "Data Sources and Methods" section), HCFA's Office of the Actuary and others believe that the spending and use numbers should be considerably higher. Readers are cautioned that the results reported in this article are those from the survey and do not reflect any estimates of potential underreporting.
Approximately $22 billion, or $600 per person, was spent for prescription drugs by or on behalf of Medicare beneficiaries in 1995 (Table 2) . Three-quarters of those dollars were spent by or on behalf of the 65 percent of beneficiaries with drug coverage. Since the survey in 1995, drug use and spending in the United States has grown rapidly. Ninety-two new drugs gained Food and Drug Administration approval in 1996 and 1997, and direct-toconsumer drug advertising has encouraged many consumers to ask for newer, more expensive drugs by name. Total U.S. drug spending between 1995 and 1997 grew by 26 percent, and the number of prescriptions filled grew by 9 percent (Levit et al., 1998 generally use more prescription drugs than younger persons) that spending growth for this group at least matched if not exceeded these national levels.
Roughly one-half of total drug spending for the Medicare population was provided by third parties, and 71 percent of national drug expenditures were paid for by third-party sources (Levit et al., 1998) . Approximately one-fourth of drug spending for Medicare beneficiaries was paid for by employer-sponsored plans, almost one-fifth by public programs, and the remainder by private sources, as shown in the next section.
PER CAPITA DRUG SPENDING
Per capita drug spending for beneficiaries with coverage was $689 in 1995; beneficiaries without coverage had per capita spending of $432. Approximately 5 million persons (14 percent) had no expenditures for prescription drugs, and another 5 million averaged expenditures of $1,250 or more (Table 3) . Insured persons were more likely to incur drug costs and more likely to incur high drug costs. Nearly onefifth of persons without coverage had no drug expenditures at all, compared with one-tenth of insured persons. The percentage of covered beneficiaries with 1995 expenditures of $1,250 or more was double that of non-covered persons. The amount of total drug spending for persons with coverage, however, varied widely by health status and the presence of any functional limitations, whether the person was disabled, and whether the person was in a risk HMO (Table 4) . Highlights of (Riley et al., 1996) . Second, HMOs often can negotiate lower drug prices for their members.
• Because Medicaid beneficiaries are generally in poorer health and more likely to have functional limitations, total drug spending was $777 for that group, higher than any other insurance category and 60 percent higher than risk HMO per capita spending. • Drug spending for females was higher than for males; white persons and black persons had higher drug spending than beneficiaries of other races; and beneficiaries with incomes greater than $30,000 had lower rates of drug spending.
DEPTH OF DRUG INSURANCE COVERAGE
Although nearly two-thirds of Medicare beneficiaries have some form of drug coverage, the extent of that coverage varies primarily according to the beneficiary's source of coverage. On average, Medicare beneficiaries with drug insurance coverage pay for onethird of their drug expenditures out of pocket. Highlights of Table 4 include the following: 
OUT-OF-POCKET COSTS
The average out-of-pocket expense (not including premium payments) for covered beneficiaries is $233. However, persons with very high total and out-of-pocket prescription drug spending tend to raise the average spending disproportionately. The distribution of out-of-pocket spending for Medicare beneficiaries with drug coverage in Table 4 illustrates the wide variation in out-of-pocket expenses. Highlights of Table 4 include the following:
• One-quarter of all covered beneficiaries spent $16 or less out of pocket in 1995 for their prescription drugs. The median out-of-pocket expense was $99.
• Median out-of-pocket expenses were less than one-half of average out-of-pocket expenses ($233) ( Table 4) . Sixty-four percent of the Medicare population paid less than the average out-of-pocket expense.
• One-quarter of beneficiaries with coverage paid more than $284. • For total drug spending, out-of-pocket costs were most affected by health status, functional limitations, and type of insurance coverage.
• Despite their likelihood to have Medicaid coverage, disabled Medicare beneficiaries age 45-64 years had such large drug expenditures that they still paid an average $350 out of their own pockets. Onequarter paid more than $400.
• Beneficiaries of all ages reporting poor health status also experienced large drug expenditures and large out-of-pocket costs-$376.
• Out-of-pocket spending was highest among covered persons with incomes of $10,000-$19,999. Averaging $260, their out-of-pocket expenditures were higher than those of persons in other income categories. Because many of these beneficiaries' incomes were above the Medicaid cutoff, they were less likely to have an employer-sponsored supplemental policy and were more likely to receive their drug benefits through an individually purchased policy.
DATA SOURCES AND METHODS

Measuring Drug Insurance Coverage
Medicare pays for about one-half of the personal health care expenditures of the average beneficiary (Olin and Liu, 1998) . Most Medicare enrollees carry additional insurance to supplement their Medicare coverage (Eppig and Chulis, 1997 Most previous studies of drug insurance coverage concentrated on coverage arising from the person's primary supplement. These studies used direct questions about whether the person's private supplementary insurance covered drugs and made reasonable assumptions about drug coverage for persons in HMOs and with Medicaid coverage. These studies produced estimates of drug insurance coverage in the Medicare population ranging from 50 to 55 percent, depending on the assumptions used and the year coverage was measured (Chulis, Eppig, and Poisal, 1995; American Association of Retired Persons, 1997) . However, there were some changes in supplementary insurance arrangements in the mid-1990s, which called into question the reasonableness of previous assumptions about drug insurance coverage. For example, as Medicaid coverage was expanded to QMBs and SLMBs, who did not necessarily receive full Medicaid benefits, it did not seem reasonable to continue to assume that all Medicaid enrollees had drug coverage. Similarly it became clear that Medicare beneficiaries in some risk HMOs were being asked to pay extra for drug benefits, and it was not clear whether it was reasonable to continue to assume that all Medicare HMO members had drug insurance benefits. Finally, Medicare beneficiaries are often very poorly informed about what Medicare and their supplementary insurance actually covers (McCall, Rice, and Sangl, 1986) , raising the question of how accurate the selfreports of private drug insurance coverage really are.
To improve the drug coverage measurement process, we used additional information from the individual prescription drug survey records to augment and verify the previously used self-reports and assumptions. In addition to collecting detailed information about every prescription drug reported on the survey, we also collected information on all the sources of payment for each prescription. Although assumptions about drug coverage can be mistaken and selfreports can be questioned, it is very unlikely that a third party would make a payment on the beneficiary's behalf for a prescription unless the person had drug insurance coverage from that source. Our initial expectation was that incorporating source-of-payment data into the drug insurance coverage decision would not change the previous levels of coverage figures very much. Contrary to our expectations of minor changes at the margin, we found that drug insurance coverage for the Medicare population was much higher than the 50-55 percent levels previously measured. As previously noted, we found that in 1995, 65 percent of Medicare beneficiaries had some form of drug insurance coverage.
We did an internal analysis to determine what factors explained this unexpectedly large increase. We previously published a drug coverage level of 50 percent in 1992, but that figure included only the Medicare population with private insurance. Using the same assumptions about drug coverage that were generally used in the early 1990s, we expanded our estimate to include the entire Medicare population living in the community. This is the same population base used in this article. We found (using the old estimation methods) that just under 53 percent of the Medicare population living in the community had drug coverage in 1992. This meant that there was a 12-percentage-point difference between 1992 (53 percent, old method) and 1995 (65 percent, new method).
We then applied the new method to 1992. The result was a measurement of 57 percent with drug coverage. This meant that, holding the method of measurement constant, the level of drug coverage increased 8 percentage points from 57 percent in 1992 to 65 percent in 1995. We believe that most of this increase was attributable to the sharp increases in HMO enrollments that were occurring at that time, and some was due to the expansion of Medicaid enrollment that was also occurring during that period.
Looking at 1992 there is a 4-percentagepoint increase between the old method (53 percent) and the new method (57 percent). This remaining difference is attributable to use of payment-source information from individual prescription drug records. More than 3 percentage points are the result of identifying persons who had drug coverage that was not from their primary supplement. These people were missed in previous analyses. The remainder of less than 1 percentage point was attributable to using the source-of-payment data to correct the drug coverage status for persons who either reported no coverage or were assumed not to have coverage. To summarize, the higher-than-expected drug coverage levels we report (12 percentage points) are attributable primarily (8 percentage points) to increased enrollments in HMOs and expansion of Medicaid rolls in the early to mid-1990s. The remaining difference (4 percentage points) came from using payment-source data in the new method. This identified a number of people who received drug benefits from a secondary source of supplementary insurance (more than 3 percentage points) that were missed by the previous method. Finally a small part (less than 1 percentage point) of the increase is explained by using payment -source data in place of yes-or-no answers about drug coverage and general assumptions about drug coverage within insurance categories.
The number of persons with secondary coverage is shown by type of primary coverage in Table 5 .
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Possible Underreporting
There is a continuing debate about the extent to which household surveys underreport the actual number of prescriptions used and their costs. Surveyed persons generally tend to recall large or traumatic medical expenses better than small, routine medical expenses. The average beneficiary is more likely to recall a hospitalization during the 4-month recall period than a visit to a doctor's office. Because most prescription drugs are not as expensive as institutional care, for example, observers tend to believe that prescription drugs are among the medical events most likely to be forgotten during an interview. In the late 1980s, when the Medicare Catastrophic Coverage legislation was being debated, some critics argued that the National Medical Expenditure Survey (NMES) survey figures being used at the time seriously underestimated prescription drug use and cost (Berk, Schur, and Mohr, 1990) . Others believed the critics were overstating the degree of the problem (Moeller and Mathiowitz, 1991) . At the time both the Congressional Budget Office and HCFA's Office of the Actuary filed reports with Congress suggesting that sur vey reports of drug use and costs could be underreported by as much as 20 percent.
In developing the field procedures for the MCBS, we tried to avoid the problems identified by critics of NMES data. Each MCBS respondent is asked each round (every 4 months) about all health care events, charges, and payments since the previous interview. Beneficiaries are asked to make notes on a calendar we provide and to retain insurance statements, payment receipts, check stubs, etc., and to bring them to the interview. For prescribed drugs, respondents are asked to retain and bring to the interview the prescription bottle, the package it came in, and any receipts or statements they received with the prescription. In addition, interviewers are furnished a list of all prescription drugs reported in the previous interview so they can ask whether the respondent has taken any of those drugs during the reporting period. Earlier surveys have tried to have such a list of drugs already reported as a prompt to recall in the next interview, but it was not always possible. Because the MCBS uses computerassisted data collection, interviewers always have the list of previously reported drugs at the next interview with the person. Although this does not ensure that prescription drugs will be recalled in the first place, it does add some assurance that those drugs that have been reported will not be lost at a later interview through poor recall. This is not to suggest that the survey underreporting problem has been solved by the MCBS. We believe that underreporting of prescription drugs still exists and is particularly a problem for one-time drugs and for poorer and sicker respondents who do not regularly use the survey recall aids. As mentioned earlier, HCFA's Office of the Actuary adjusts MCBS spending amounts upward. We do believe, however, that the MCBS drug information collection procedures are an improvement over survey methods used in earlier surveys.
Establishing Payment Amounts
Whenever possible, the actual transaction price for each prescribed drug is used, not the listed or posted price to which discounts (e.g., senior citizen discounts) are sometimes applied. A variety of methods were developed to determine a reasonable transaction price when respondents knew the amount they paid out of pocket but did not know the total transaction price. (For example, when other public or private sources made all or most of the payment on their behalf.)
The first step is to look within the MCBS data base to see if a total price is reported for that drug in that form and in that amount. If none is reported, a published drug industry source is consulted that gives the average national wholesale price. However, because of discounts, purchasers may pay different prices for the same drug. For example, an individual purchasing a prescription at a local pharmacy generally pays more than a Department of Veterans Affairs (VA) hospital pays for the same drug. Information on typical discounts is obtained from average prices that bulk buyers such as HMOs, the VA, and State Medicaid programs paid. In retail pharmacies, price markups vary according to wholesale price. For example, for prescriptions with average prices below $5, the final price was more than double that amount on average. For prescriptions with prices above $20, on the other hand, the average pharmacy markup was much smaller.
The result of this process was to establish an average transaction price for certain drugs and specific payers. In individual cases, the average payment may actually have been more or less than the average price we established. But we believe our final price is a reasonable estimate of the total price paid for a given drug. In allocating total payments among the various sources of payment, 2 percent of payments had to be classified as coming from an unknown payment source.
SUMMARY
Prescription drugs have become an increasingly important component of health care and are currently not part of the Medicare benefit. Two-thirds of Medicare beneficiaries have pieced together some form of drug coverage, but it is not always extensive.
The largest source of coverage comes from employer-sponsored insurance, a source that has begun to diminish. Persons in the youngest age group, those never married, and those in the highest income category ($30,000 or more) are the most likely to have coverage.
On average, covered persons still pay one-third of their drug expenditures out of pocket, not counting any premium payments they may make as well. Nevertheless, they are more likely to incur drug costs and high drug costs than those without any coverage, even though the health status of the two groups is similar.
